Surf Therapeutics reports positive first-in-human RA data — second bioelectronic medicine company with human proof
Summary
Surf Therapeutics reported positive first-in-human data from their bioelectronic rheumatoid arthritis clinical study in early 2026, secured additional financing bringing total funding to $6M. Their results come shortly after Setpoint Medical's landmark Nature publication of their larger VNS RA pivotal trial, establishing a second company with human evidence for bioelectronic medicine in autoimmune disease. Surf's early data suggests their specific peripheral nerve target and stimulation parameters produce measurable anti-inflammatory effects.
Why it matters
A second company reporting positive first-in-human bioelectronic RA data — even at the early feasibility stage — powerfully reinforces that the cholinergic anti-inflammatory pathway is a real and reproducible therapeutic target. Multiple early-stage companies generating positive RA data will accelerate regulatory familiarity with bioelectronic medicine as a new therapeutic class.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial